Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survival.
Julia OhlingerDirk VordermarkChristian OstheimerMatthias BacheTherese TzschoppeKamil DemircanLutz SchomburgDaniel MedenwaldBarbara SeligerPublished in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2024)
Especially patients with increasing selenium levels during radiotherapy showed an improved overall survival. Thus, serum selenium might be a predictive factor for OS in NSCLC patients. The value of supplementation of the trace element is subject to future research.
Keyphrases
- small cell lung cancer
- squamous cell carcinoma
- early stage
- end stage renal disease
- locally advanced
- newly diagnosed
- radiation therapy
- ejection fraction
- radiation induced
- advanced non small cell lung cancer
- chronic kidney disease
- prognostic factors
- free survival
- brain metastases
- epidermal growth factor receptor
- patient reported